Debut Biotechnology, a UC-Irvine spinout that is advancing scalable cell-free biomanufacturing, closed a $2.6M seed funding round.
The round was led by KdT Ventures, with participation from Better Ventures, FTW Ventures, and SpringTide Ventures.
The funding will be used to support these integrations, expand business development, double the science team, and create a pilot production system.
Founded by Joshua Britton, Greg Wess, and Brady Beauchamp, Debut Bio provides pharmaceutical and specialty chemical industries with tools to manufacture high-value molecules by combining custom-designed immobilized enzymes with continuous biomanufacturing processes. Through the utilization of plug-and-play enzyme cartridges, the company’s cell-free platform has the ability to transform bio-renewable materials into therapeutics and specialty chemicals. The company has currently partnered with two large manufacturers to integrate its platform into their existing pipelines.